JMP Securities reiterated coverage on CTI BioPharma with a new price target

3/2/22 8:15:44 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

JMP Securities reiterated coverage of CTI BioPharma with a rating of Market Outperform and set a new price target of $5.00 from $4.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CTIC

Date	Price Target	Rating	Analyst
10/17/2022	$13.00	Outperform	SVB Leerink
9/1/2022	$13.00	Buy	Jefferies
7/7/2022	$10.00	Outperform	Cowen
3/2/2022	$4.00 → $5.00	Market Outperform	JMP Securities
3/2/2022	$5.00 → $8.00	Buy	Needham
12/1/2021	$6.00 → $5.00	Buy	Needham
8/9/2021	$7.00	Buy	BTIG Research